share_log

Vertex Pharmaceuticals | SC TO-T/A: Third party tender offer statement (Amendment)

Vertex Pharmaceuticals | SC TO-T/A: Third party tender offer statement (Amendment)

福泰制药 | SC TO-T/A：发行招标公告
美股SEC公告 ·  05/10 08:04
Moomoo AI 已提取核心信息
Vertex Pharmaceuticals Incorporated, through its wholly owned subsidiary Adams Merger Sub, Inc., has announced an amendment to its tender offer to acquire all outstanding shares of Alpine Immune Sciences, Inc. The offer, initially filed with the SEC on April 22, 2024, proposes a purchase price of $65.00 per share in cash. The tender offer is set to expire at 11:59 p.m. ET on May 17, 2024, unless extended. A key condition of the offer, the expiration of the waiting period under the HSR Act, was met on May 9, 2024, as both Vertex and Alpine filed their respective HSR Notification Forms with the FTC and the DOJ. The successful completion of this waiting period satisfies one of the conditions for the offer's consummation. The terms and conditions of the offer are detailed in the Offer to Purchase and the accompanying Letter of Transmittal, which are filed with the SEC. The amendment was signed by Jonathan Biller, Secretary of Adams Merger Sub, Inc., and Executive Vice President and Chief Legal Officer of Vertex Pharmaceuticals Incorporated, on May 10, 2024.
Vertex Pharmaceuticals Incorporated, through its wholly owned subsidiary Adams Merger Sub, Inc., has announced an amendment to its tender offer to acquire all outstanding shares of Alpine Immune Sciences, Inc. The offer, initially filed with the SEC on April 22, 2024, proposes a purchase price of $65.00 per share in cash. The tender offer is set to expire at 11:59 p.m. ET on May 17, 2024, unless extended. A key condition of the offer, the expiration of the waiting period under the HSR Act, was met on May 9, 2024, as both Vertex and Alpine filed their respective HSR Notification Forms with the FTC and the DOJ. The successful completion of this waiting period satisfies one of the conditions for the offer's consummation. The terms and conditions of the offer are detailed in the Offer to Purchase and the accompanying Letter of Transmittal, which are filed with the SEC. The amendment was signed by Jonathan Biller, Secretary of Adams Merger Sub, Inc., and Executive Vice President and Chief Legal Officer of Vertex Pharmaceuticals Incorporated, on May 10, 2024.
Vertex Pharmicals Incorporated通过其全资子公司Adams Merger Sub, Inc. 宣布修订其收购阿尔卑斯免疫科学公司所有已发行股份的要约。该要约最初于2024年4月22日向美国证券交易委员会提出，收购价为每股65.00美元的现金。除非延期，否则要约将于美国东部时间2024年5月17日晚上 11:59 到期。该提议的一个关键条件，即《高铁法》规定的等待期的到期，已于2024年5月9日得到满足，因为Vertex和Alpine都向联邦贸易委员会和司法部提交了各自的高铁通知表。成功完成这段等待期满足了报价完成的条件之一。向美国证券交易委员会提交的收购要约和随附的送文函中详细介绍了要约的条款和条件。该修正案由亚当斯合并子公司秘书兼Vertex Pharmicals Incorporated执行副总裁兼首席法务官乔纳森·比勒于2024年5月10日签署。
Vertex Pharmicals Incorporated通过其全资子公司Adams Merger Sub, Inc. 宣布修订其收购阿尔卑斯免疫科学公司所有已发行股份的要约。该要约最初于2024年4月22日向美国证券交易委员会提出，收购价为每股65.00美元的现金。除非延期，否则要约将于美国东部时间2024年5月17日晚上 11:59 到期。该提议的一个关键条件，即《高铁法》规定的等待期的到期，已于2024年5月9日得到满足，因为Vertex和Alpine都向联邦贸易委员会和司法部提交了各自的高铁通知表。成功完成这段等待期满足了报价完成的条件之一。向美国证券交易委员会提交的收购要约和随附的送文函中详细介绍了要约的条款和条件。该修正案由亚当斯合并子公司秘书兼Vertex Pharmicals Incorporated执行副总裁兼首席法务官乔纳森·比勒于2024年5月10日签署。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息